Skip to main content
Pharnext logo

Pharnext — Investor Relations & Filings

Ticker · ALPHA ISIN · FR0011191287 LEI · 969500KJGF9ZUYXSMJ27 Euronext Growth Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2023-10-24 Share Issue/Capital Cha…
Country FR France
Listing Euronext Growth ALPHA

About Pharnext

https://pharnext.com/

Pharnext is an advanced clinical-stage biopharmaceutical company that develops novel therapeutics for neurodegenerative diseases lacking curative or satisfactory treatments. The company's approach is based on its proprietary Pleotherapy™ platform, which uses network pharmacology to identify and develop synergistic combinations of already-approved drugs at new, lower doses. This strategy aims to create more effective and safer treatments. Pharnext's lead product candidate, PXT3003, is an oral fixed-dose combination therapy in development for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating inherited peripheral neuropathy.

Recent filings

Filing Released Lang Actions
Ajustement de la valeur nominale
Share Issue/Capital Change Classification · 1% confidence The document is a press release ('Communiqué de presse') dated October 24, 2023, announcing a capital reduction ('réduction de capital') achieved by lowering the nominal value of the shares from 0.10 euro to 0.01 euro. This action directly impacts the company's capital structure and share count. This falls under the definition of Capital/Financing Update (CAP), as it is a specific change to the capital structure, distinct from a general share issue (SHA) or a buyback (POS). Although it is a financing activity, 'CAP' is the most precise fit for a capital reduction decision.
2023-10-24 French
Levée de fonds de 0,5 million d'euros
Capital/Financing Update Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces a specific financial transaction: a fundraising effort ("Levée de fonds de 0,5 million d'euros") involving the issuance of convertible bonds with warrants (OCEANE-BSA). This directly relates to the company's capital structure and financing activities. Based on the definitions, the most appropriate category is 'Capital/Financing Update' (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it details a specific capital event.
2023-10-19 French
Levée de fonds de 0,5 million d'euros
Capital/Financing Update Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces a specific financial transaction: a "Levée de fonds de 0,5 million d'euros" (Fundraising of 0.5 million euros) via the issuance of OCEANE-BSA. This directly relates to the company's financing activities and capital structure changes. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a simple announcement of a report (RPA/RNS), as it details the specifics of the capital raise itself.
2023-10-18 French
Pharnext annonce avoir reçu deux offres valorisant son candidat médicament dans la maladie de Charcot-Marie-Tooth de type 1A à plus de 250 MEUR et lève 2,5 MEUR
Capital/Financing Update Classification · 1% confidence The document is a press release from Pharnext dated October 16, 2023. It announces two key financial/corporate events: 1) Receiving two binding offers valuing their drug candidate PXT3003 at over €250M, and 2) Raising an additional €2.5M in short-term financing via OCEANE-BSA issuance. This content relates to corporate financing activities, asset valuation, and capital structure updates, but it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a dividend notice (DIV). It is a specific announcement detailing fundraising and major asset transactions/negotiations. The closest fit among the provided codes is 'Capital/Financing Update' (CAP), as it explicitly discusses raising capital (€2.5M) and major financing/valuation milestones related to a key asset.
2023-10-16 French
Pharnext received two offers valuing its drug candidate for Charcot-Marie-Tooth disease type 1A at more than EUR 250m, and raises EUR 2.5m
Capital/Financing Update Classification · 1% confidence The document is a press release dated October 16, 2023, announcing that Pharnext has received two offers valuing its drug candidate PXT3003 at over €250 million. It also mentions securing an additional financing of €2.5 million via OCEANE-BSA bonds to cover short-term needs while reviewing the offers. This announcement details significant corporate financing activities, potential asset monetization (licensing/sale), and capital structure updates (terminating/modifying the GTO 13 financing line). This content aligns best with 'Capital/Financing Update' (CAP), as the primary focus is on fundraising, asset valuation offers, and related financing agreements, rather than a formal regulatory report (like 10-K or IR) or a simple dividend/insider trade notice. The document length (7061 chars) is substantial enough to be a primary announcement, not just a brief RPA.
2023-10-16 English
Information relative au nombre total de droits de vote et d'actions composant le capital social et à la valeur nominale des actions
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and its primary content is the official announcement of the total number of voting rights and shares composing the share capital as of a specific date (30/09/2023), referencing French commercial code and AMF regulations (Article L.233-8 II and Article 223-16). This type of mandatory disclosure regarding the capital structure and voting rights is a specific regulatory filing requirement in France. While it relates to share capital, it is not a general share issue announcement (SHA) or a transaction in own shares (POS), but rather a periodic statement of the total outstanding shares and voting rights. This fits best under the general category for regulatory announcements that are not covered by more specific financial reports or corporate actions, which points towards 'Regulatory Filings' (RNS). However, given the specific nature of reporting total shares and voting rights, it is often classified separately or under a category related to capital structure updates. Reviewing the definitions, 'Share Issue/Capital Change' (SHA) is for announcements of *new* issues or splits, not the periodic reporting of the total count. 'Regulatory Filings' (RNS) is the most appropriate fallback for mandatory, periodic regulatory disclosures that don't fit elsewhere. The document is a formal announcement, not a detailed report or a simple notice of a report being published (RPA).
2023-10-10 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.